The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates

Carcinogenesis

Volumn 29, Issue 5, 2008, Pages 1077-1082

  Fritz, Wayne A ^a   Lin, Tien Min ^a   Peterson, Richard E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VANADIC ACID; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION FUNCTION; DIMERIZATION; ENZYME PHOSPHORYLATION; FEMALE; GENOTYPE; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TISSUE CULTURE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; DIMERIZATION; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; TRANSPLANTATION, HETEROLOGOUS; VANADATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47249128122     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn069     Document Type: Article

References (52)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
2. Abate-Shen,C. et al. (2000) Molecular genetics of prostate cancer. Genes Dev., 14, 2410-2434.
3. DeMarzo,A.M. et al. (2003) Pathological and molecular aspects of prostate cancer. Lancet, 361, 955-964.
4. Feldman,B.J. et al. (2001) The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1, 34-45.
5. Grossmann,M.E. et al. (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst., 93 1687-1697.
6. Cox,M.C. et al. (2005) Angiogenesis and prostate cancer: Important laboratory and clinical findings. Curr. Oncol. Rep., 7, 215-219.
7. Lara,P.N.Jr et al. (2004) Angiogenesis-targeted therapies in prostate cancer. Clin. Prostate Cancer, 3, 165-173.
8. Ferrara,N. et al. (1997) The biology of vascular endothelial growth factor. Endocr. Rev., 18, 4-25.
9. Harper,M.E. et al. (1996) Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br. J. Cancer, 74, 910-916.
10. Borre,M. et al. (2000) Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res., 6, 1882-1890.
11. Ferrer,F.A. et al. (1997) Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 157, 2329-2333.
12. Jones,A. et al. (2000) Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int., 85, 276-280.
13. Forsythe,J.A. et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16, 4604-4613.
14. Marti,H.H. et al. (1998) Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl Acad. Sci. USA, 95, 15809-15814.
15. Jiang,B.H. et al. (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369.
16. Zhong,H. et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60, 1541-1545.
17. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
18. Fresno Vara,J.A. et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev., 30, 193-204.
19. Hankinson,O. (1995) The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol., 35, 307-340.
20. Song,J. et al. (2002) A ligand for the aryl hydrocarbon receptor isolated from lung. Proc. Natl Acad. Sci. USA, 99, 14694-14699.
21. Henry,E.C. et al. (2006) A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch. Biochem. Biophys., 450, 67-77.
22. Kashani,M. et al. (1998) Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. Prostate, 37, 98-108.
23. Fernandez-Salguero,P. et al. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 268, 722-726.
24. Schmidt,J.V. et al. (1996) Characterization of a murine Ahr null allele: Involvement of the Ah receptor in hepatic growth and development. Proc. Natl Acad. Sci. USA, 93, 6731-6736.
25. Mimura,J. et al. (1997) Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ab (dioxin) receptor. Genes Cells, 2, 645-654.
26. Greenberg,N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA, 92, 3439-3443.
27. Gingrich,J.R. et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res., 56, 4096-4102.
28. Gingrich,J.R. et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res., 57, 4687-4691.
29. Hsu,C.X. et al. (1998) Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J. Urol., 160 1500-1505.
30. Fritz,W.A. et al. (2007) The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis, 28, 497-505.
31. Kaplan-Lefko,P.J. et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55, 219-237.
32. Huss,W.J. et al. (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res., 61, 2736-2743.
33. Thackaberry,E.A. et al. (2002) Aryl hydrocarbon receptor null mice develop cardiac hypertropby and increased hypoxia-inducible factor-Ialpha in the absence of cardiac hypoxia. Cardiovasc. Toxicol. 2, 263-274.
34. Gao,N. et al. (2002) Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidy-linositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem., 277, 31963-31971.
35. Benedict,J.C. et al. (2000) Physiological role of the aryl hydrocarbon receptor in mouse ovary development. Toxicol. Sci., 56, 382-388.
36. Lin,T.-M. et al. (2002) Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice. Toxicol. Sci., 68 479-487.
37. Hsing,A.W. et al. (2001) Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J. Natl Cancer Inst. 93, 783-789.
38. Ali,I.U. et al. (1999) Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst., 91, 1922-1932.
39. Li,J. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-1947.
40. Steck,P.A. et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15, 356-362.
41. Teng,D.H. et al. (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res., 57, 5221-5225.
42. Cantley,L.C. et al. (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA, 96, 4240-4245.
43. Di Cristofano,A. et al. (2000) The multiple roles of PTEN in tumor suppression. Cell, 100, 387-390.
44. Kwabi-Addo,B. et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl Acad. Sci. USA, 98, 11563-11568.
45. Carver,L.A. et al. (1994) Tissue specific expression of the rat Ah-receptor and ARNT mRNAs. Nucleic Acids Res., 22, 3038-3044.
46. Roman,B.L. et al. (1998) Responsiveness of the adult male rat reproductive tract to 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: Ah receptor and ARNT expression, CYP1A1 induction, and Ah receptor down-regulation. Toxicol. Appl. Pharmacol., 150, 228-239.
47. Lin,T.M. et al. (2001) Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-p dioxin-exposed male mice. J. Toxicol. Environ. Health A, 64 327-342.
48. Thackaberry,E.A. et al. (2005) Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on murine heart development: alteration in fetal and postnatal cardiac growth, and postnatal cardiac chronotropy. Toxicol. Sci., 88, 242-249.
49. Ivnitski-Steele,I.D. et al. (2003) Vascular endothelial growth factor rescues 2,3,7,8-tetrachlorodibenzo-p-dioxin inhibition of coronary vasculogenesis. Birth Defects Res. A Clin. Mol. Teratol., 67, 496-503.
50. Piskorska-Pliszczynska,J. et al. (1991) Mechanism of action of 2,3,7,8- tetrachlorodibenzo-p-dioxin antagonists: Characterization of 6-[125I]-methyl-8-iodo-1,3-dichlorodibenzofuran-Ah receptor complexes. Arch. Biochem. Biophys., 284, 193-200.
51. Morrow,D. et al. (2004) Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol., 88, 27-36.
52. Nachshon-Kedmi,M. et al. (2004) Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3′-diindolylmethane through the mitochondrial pathway. Br. J. Cancer, 91, 1358-1363.